Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | tumor protein p53 | Starlite/ChEMBL | No references |
Homo sapiens | GNAS complex locus | Starlite/ChEMBL | No references |
Homo sapiens | nuclear factor, erythroid 2-like 2 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Schistosoma mansoni | GTP-binding protein alpha subunit gna | GNAS complex locus | 394 aa | 450 aa | 28.7 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | glutathione reductase | 0.0138 | 0.2508 | 1 |
Plasmodium vivax | thioredoxin reductase, putative | 0.0138 | 0.2508 | 1 |
Loa Loa (eye worm) | glutathione reductase | 0.0138 | 0.2508 | 1 |
Mycobacterium ulcerans | dihydrolipoamide dehydrogenase | 0.0048 | 0 | 0.5 |
Trypanosoma brucei | trypanothione reductase | 0.0138 | 0.2508 | 1 |
Plasmodium falciparum | glutathione reductase | 0.0138 | 0.2508 | 1 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0055 | 0.0204 | 0.0204 |
Plasmodium vivax | glutathione reductase, putative | 0.0138 | 0.2508 | 1 |
Mycobacterium leprae | DIHYDROLIPOAMIDE DEHYDROGENASE LPD (LIPOAMIDE REDUCTASE (NADH)) (LIPOYL DEHYDROGENASE) (DIHYDROLIPOYL DEHYDROGENASE) (DIAPHORASE | 0.0048 | 0 | 0.5 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 0.0204 | 0.0812 |
Echinococcus multilocularis | thioredoxin glutathione reductase | 0.0138 | 0.2508 | 0.2508 |
Brugia malayi | GTP-binding regulatory protein Gs alpha-S chain, putative | 0.0055 | 0.0204 | 0.0812 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 0.0204 | 0.0812 |
Mycobacterium ulcerans | flavoprotein disulfide reductase | 0.0048 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.006 | 0.0328 | 0.0541 |
Mycobacterium tuberculosis | NADPH-dependent mycothiol reductase Mtr | 0.0138 | 0.2508 | 1 |
Toxoplasma gondii | thioredoxin reductase | 0.0138 | 0.2508 | 1 |
Wolbachia endosymbiont of Brugia malayi | dihydrolipoamide dehydrogenase E3 component | 0.0048 | 0 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | dihydrolipoamide dehydrogenase E3 component | 0.0048 | 0 | 0.5 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0055 | 0.0204 | 0.0204 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 0.0204 | 0.0812 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0055 | 0.0204 | 0.0204 |
Loa Loa (eye worm) | thioredoxin reductase | 0.0138 | 0.2508 | 1 |
Onchocerca volvulus | 0.006 | 0.0328 | 0.5 | |
Trichomonas vaginalis | glutathione reductase, putative | 0.0048 | 0 | 0.5 |
Trypanosoma cruzi | trypanothione reductase, putative | 0.0138 | 0.2508 | 1 |
Mycobacterium ulcerans | dihydrolipoamide dehydrogenase, LpdB | 0.0048 | 0 | 0.5 |
Treponema pallidum | NADH oxidase | 0.0048 | 0 | 0.5 |
Schistosoma mansoni | cellular tumor antigen P53 | 0.006 | 0.0328 | 0.1308 |
Trichomonas vaginalis | mercuric reductase, putative | 0.0048 | 0 | 0.5 |
Brugia malayi | Thioredoxin reductase | 0.0138 | 0.2508 | 1 |
Echinococcus granulosus | thioredoxin glutathione reductase | 0.0138 | 0.2508 | 0.2508 |
Chlamydia trachomatis | dihydrolipoyl dehydrogenase | 0.0048 | 0 | 0.5 |
Echinococcus multilocularis | tumor protein p63 | 0.0408 | 1 | 1 |
Leishmania major | trypanothione reductase | 0.0138 | 0.2508 | 1 |
Plasmodium falciparum | thioredoxin reductase | 0.0138 | 0.2508 | 1 |
Giardia lamblia | NADH oxidase lateral transfer candidate | 0.0048 | 0 | 0.5 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0055 | 0.0204 | 0.0204 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 2.9093 uM | PUBCHEM_BIOASSAY: Nrf2 qHTS screen for inhibitors. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493153, AID493163, AID504648] | ChEMBL. | No reference |
Potency (functional) | 11.2202 uM | PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 15.8489 um | PUBCHEM_BIOASSAY: qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature. (Class of assay: confirmatory) [Related pubchem assays: 902 ] | ChEMBL. | No reference |
Potency (functional) | 18.526 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 20.5962 uM | PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 31.6228 um | PUBCHEM_BIOASSAY: qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 32.6427 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID540262] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.